| Literature DB >> 30030364 |
Lisa Tilokani1, Shun Nagashima1, Vincent Paupe1, Julien Prudent2.
Abstract
Mitochondria are highly dynamic organelles undergoing coordinated cycles of fission and fusion, referred as 'mitochondrial dynamics', in order to maintain their shape, distribution and size. Their transient and rapid morphological adaptations are crucial for many cellular processes such as cell cycle, immunity, apoptosis and mitochondrial quality control. Mutations in the core machinery components and defects in mitochondrial dynamics have been associated with numerous human diseases. These dynamic transitions are mainly ensured by large GTPases belonging to the Dynamin family. Mitochondrial fission is a multi-step process allowing the division of one mitochondrion in two daughter mitochondria. It is regulated by the recruitment of the GTPase Dynamin-related protein 1 (Drp1) by adaptors at actin- and endoplasmic reticulum-mediated mitochondrial constriction sites. Drp1 oligomerization followed by mitochondrial constriction leads to the recruitment of Dynamin 2 to terminate membrane scission. Inner mitochondrial membrane constriction has been proposed to be an independent process regulated by calcium influx. Mitochondrial fusion is driven by a two-step process with the outer mitochondrial membrane fusion mediated by mitofusins 1 and 2 followed by inner membrane fusion, mediated by optic atrophy 1. In addition to the role of membrane lipid composition, several members of the machinery can undergo post-translational modifications modulating these processes. Understanding the molecular mechanisms controlling mitochondrial dynamics is crucial to decipher how mitochondrial shape meets the function and to increase the knowledge on the molecular basis of diseases associated with morphology defects. This article will describe an overview of the molecular mechanisms that govern mitochondrial fission and fusion in mammals.Entities:
Keywords: Dynamin family; ER-Actin; Mitochondrial dynamics; Molecular Mechanisms; Regulation
Mesh:
Substances:
Year: 2018 PMID: 30030364 PMCID: PMC6056715 DOI: 10.1042/EBC20170104
Source DB: PubMed Journal: Essays Biochem ISSN: 0071-1365 Impact factor: 8.000
Figure 1The mitochondrial morphology network
Representative microscopy confocal images showing the different mitochondrial morphological aspects from control (Ctrl), Mfn1- and Drp1-Knockdown (Kd) mouse embryonic fibroblasts cells. Mitochondria are labelled with an anti-TOM20 antibody (OMM marker). Tubular, fragmented and hyperfused mitochondria are highlighted by zoomed areas (white squares); scale bars: 10 μm. Please note that the bright TOM20-positive structure in the zoom area of the Drp1-Kd is not a mitochondrial fragment but a mitochondria-derived vesicle [192].
Figure 2Schematic representation of the structural elements of the fission and fusion proteins, and their associated post-translational modifications
Illustration of the core machinery proteins involved in (A) mitochondrial fission and (B) fusion. The classical model proposes that Mfns contain two transmembrane (TM) domains in between HR1 and HR2 domains. Alternatively, Mfns have been recently demonstrated to have only one TM that lies between the two HR domains. Cysteine residues, sensitive to oxidative stress are located in the C-terminal located in the IMS (only Mfn2 structural domains are represented but this new topology is also applicable to Mfn1). Domains are depicted in different colours. Identified location of post-translational modifications are indicated by P (Phosphorylation), N (S-nitrosylation), S (SUMOylation), G (O-GLcNAcylation), A (Acetylation) or U (Ubiquitination); BSE, bundle signalling elements; CC, coil-coil; GED, GTPase effector domain; HR, heptad repeat; MTS, mitochondrial targeting sequence; NTD, nucleotidyl transferase domains; PH, Pleckstrin homology; PR, Proline rich; RR, repeat regions; TM, transmembrane.
Figure 3Simplified models for mitochondrial fusion in mammals
(A) Schematic representations of mitochondrial fusion, based on the Mfns topology suggesting two TM domains with both the HR1 and HR2 domains facing the cytosol. (1) The outer membrane of two opposing mitochondria are tethered by the interaction in trans of the HR2 and/or GTPase domains of Mfns. GTP binding or/and hydrolysis induce Mfns conformational change leading to mitochondrial docking and to an increase of membrane contact sites. For clarity reasons, not all of the recent suggested models leading to Mfns dimerization and conformational change are highlighted in the scheme. (3) Finally, GTPase-dependent power stroke or GTP-dependent oligomerization ensure OMM fusion. The composition of the OMM in phospholipids can also regulate this process. (4) Following OMM fusion, OPA1 and CL drive IMM fusion. The interaction between OPA1 and CL on either side of the membrane tethers the two IMM, which fuse following OPA1-depedent GTP hydrolysis (5). In this model, S-OPA1 has been shown to enhance OPA1–CL interaction and fusion. Please note that after OMM and IMM fusion, Mfn2 and OPA1, as membrane-bound proteins, are still present on the different membranes but are disassembled. (B) Schematic representations of OMM fusion based on the new metazoan Mfns topology suggesting only one TM placing the Mfn C-terminus in the IMS. Oxidized environment in the IMS (ROS production) and increase concentration of GSSG lead to the establishment of two disulphide bonds within the IMS domain. These redox-mediated disulphide modifications induce the dimerization and oligomerization of Mfns molecules which may promote tethering or GTPase activity required for OMM fusion. Interestingly, this redox-regulated Mfns oligomerization is a dynamic and reversible process. Yellow stars indicate an oxidized environment.
Figure 4Simplified model for mitochondrial fission in mammals
Schematic representation of the multi-step processes required for mitochondria division. (1) In the matrix, replication of the mtDNA marks the site for ER-recruitment. In parallel, Drp1 oligomers are in constant balance between the cytosol and mitochondria. In addition, IMM constriction occurs at mitochondria–ER contacts in a Ca2+-dependent process, before Drp1 oligomerization and maturation. (2) Oligomeric forms of Drp1 accumulate at ER-sites where the pre-constriction of the membrane has been initiated. (3) The zoomed area highlights the factors regulating mitochondrial division. The ER-bound INF2 and mitochondrial Spire1C induce actin nucleation and polymerization at mitochondria–ER contact sites. The Myosin IIa may ensure actin cable contraction, providing the mechanical force to drive mitochondria pre-constriction. At these sites, MFF and MiDs recruit Drp1 where it oligomerizes in a ring-like structure and (4) GTP-hydrolysis leads to conformational change, enhancing pre-existing mitochondrial constriction. The composition of the OMM in phospholipids also regulates Drp1 assembly and activity. (5) Then, Dnm2 is recruited to Drp1-mediated mitochondrial constriction neck where it assembles and terminates membrane scission, (6) leading to two daughter mitochondria. (7) The mechanisms of disassembly of the fission machinery following division remain unclear but both adaptors and Drp1 are found at both mitochondrial tips after division.
Clinical syndromes due to mutations in genes encoding fission and fusion machinery components
| Gene | OMIM | Inheritance | Disease | Symptoms | Refs |
|---|---|---|---|---|---|
| 608507 | AD | Charcot–Marie–Tooth disease type 2A | Distal limb muscle weakness and atrophy, axonal degeneration/regeneration, areflexia, distal sensory loss (pain and temperature more frequent) with or without: (a) CNS involvement (cognitive decline, spasticity, encephalopathy), (b) optic atrophy, (c) hearing loss and (d) vocal cord paresis | [ | |
| AR | Charcot–Marie–Tooth disease type 2A | [ | |||
| AD | Hereditary motor and sensory neuropathy VIA | [ | |||
| 605290 | AD | Optic atrophy 1 | Progressive loss of visual acuity, temporal optic nerve pallor, central scotoma with or without: (a) CNS (ataxia, spasticity, hearing loss) and (b) PNS (axonal sensorineural polyneuropathy) symptoms. | [ | |
| AD | Optic atrophy plus syndrome | [ | |||
| AR | Behr syndrome | Early-onset optic atrophy accompanied by neurologic features, including ataxia, pyramidal signs, spasticity and mental retardation | [ | ||
| 617619 | AR/AD | Myopathy and ataxia | Hand and feet muscle weakness, growth impairment, fine tremor, cerebellar hypotrophy with or without: (a) white matter hyperintensities, (b) frontal lobe atrophy and (c) mental retardation | [ | |
| 603850 | AR/AD | Encephalopathy | Abnormal brain development, seizures, hepatic dysfunction, encephalopathy, dysmorphism. | [ | |
| AD | Optic atrophy 5 | Progressive loss of visual acuity, optic nerve atrophy and central scotoma | [ | ||
| 614785 | AR | Encephalopathy | Seizures, dysphagia, optic and peripheral neuropathy, developmental delay, microcephaly, cerebellar atrophy and basal ganglia lesions | [ | |
| 615498 | AR | Mitochondrial myopathy | Progressive muscle weakness, intermittent muscle pain and exercise intolerance | [ | |
| 602378 | AD | Centronuclear myopathy 1 | Slowly progressive muscle weakness. | [ | |
| AD | Charcot–Marie–Tooth disease, axonal type 2M | Distal limb muscle weakness and atrophy and sensory impairment, areflexia +/-neutropenia. | [ | ||
| AD | Charcot–Marie–Tooth disease, dominant intermediate B | ||||
| AR | Lethal congenital contracture syndrome 5 | Polyhydramnios, decreased foetal movements, intracranial bleeding, retinal haemorrhage, joint contractures and respiratory insufficiency | |||
| 610826 | AR | Pontocerebellar hypoplasia type 1 | Early onset of optic atrophy, peripheral axonal sensorimotor neuropathy, ataxia, myoclonus, cerebellar atrophy, hypotonia with variable degree of severity, age at onset and association of symptoms | [ | |
| AR | Hereditary sensory motor neuropathy | [ | |||
| AR | Optic atrophy spectrum disorders | [ | |||
| 606598 | AR | Charcot–Marie–Tooth disease type 4A | Distal limb muscle weakness and atrophy and sensory impairment, areflexia with or without: (a) axonal regeneration and (b) vocal cord paresis | [ | |
| AR/AD | Charcot–Marie–Tooth disease type 2K | ||||
| AR | Charcot–Marie–Tooth disease type A | ||||
| AR | Charcot–Marie–Tooth disease with vocal cord paresis | ||||
| 610982 | AD | Charcot–Marie–Tooth disease type E | Distal limb muscle weakness and atrophy and sensory impairment, areflexia, sensorineural hearing loss and foot drop | [ | |
| AD | Focal segmental glomerulosclerosis | Proteinuria and renal failure | [ |
A non-exhaustive list of the diseases related to the principal identified mutations in genes encoding the core components of mitochondrial dynamics with associated symptoms. Abbreviations: AD, autosomal dominant; AR, autosomal recessive; CNS, central nervous system; OMIM, Online Mendelian Inheritance in Man®; PNS, peripheral nervous system.